XML 51 R35.htm IDEA: XBRL DOCUMENT
v3.26.1

Segment Reporting (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2026
Segment Reporting [Abstract] |
Schedule of Company’s Segment | The following table presents the Company’s segment results (unaudited) for the three months ended March 31, 2026 and 2025: Schedule of Company’s Segment
|  | Medical Device |  |  | Digital Commodities |  |  | Corporate |  |  | Consolidated |  |  | Medical Device |  |  | Corporate |  |  | Consolidated |
|  | THREE MONTHS ENDED MARCH 31, 2026 |  |  | THREE MONTHS ENDED MARCH 31, 2025 |
|  | Medical Device |  |  | Digital Commodities |  |  | Corporate |  |  | Consolidated |  |  | Medical Device |  |  | Corporate |  |  | Consolidated |
Net Revenue |  | $ | 192,780 |  |  | $ | - |  |  | $ | - |  |  | $ | 192,780 |  |  | $ | - |  |  | $ | - |  |  | $ | - |
Cost of goods sold |  |  | 202,578 |  |  |  | - |  |  |  | - |  |  |  | 202,578 |  |  |  | - |  |  |  | - |  |  |  | - |
Total Cost of Goods Sold |  |  | 202,578 |  |  |  | - |  |  |  | - |  |  |  | 202,578 |  |  |  | - |  |  |  | - |  |  |  | - |
Gross Margin (Loss) |  |  | (9,798 | ) |  |  | - |  |  |  | - |  |  |  | (9,798 | ) |  |  | - |  |  |  | - |  |  |  | - |
Staking revenue, net |  |  | - |  |  |  | 3,134,109 |  |  |  | - |  |  |  | 3,134,109 |  |  |  | - |  |  |  | - |  |  |  | - |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consulting fees – related parties |  |  | - |  |  |  | 2,500,000 |  |  |  | - |  |  |  | 2,500,000 |  |  |  | - |  |  |  |  |  |  |  | - |
Selling, general and administrative |  |  | 175,488 |  |  |  | 438,209 |  |  |  | 4,439,622 |  |  |  | 5,053,320 |  |  |  | 427,082 |  |  |  | 937,214 |  |  |  | 1,364,296 |
Research and development |  |  | - |  |  |  | - |  |  |  | 137,097 |  |  |  | 137,097 |  |  |  | - |  |  |  | - |  |  |  | - |
Unrealized loss on digital commodities |  |  | - |  |  |  | 70,846,202 |  |  |  | - |  |  |  | 70,846,202 |  |  |  | - |  |  |  | - |  |  |  | - |
Realized loss on digital commodities |  |  | - |  |  |  | 10,789,841 |  |  |  | - |  |  |  | 10,789,841 |  |  |  | - |  |  |  | - |  |  |  | - |
Digital commodity transaction expenses |  |  | - |  |  |  | 63,821 |  |  |  | - |  |  |  | 63,821 |  |  |  | - |  |  |  | - |  |  |  | - |
Total Operating Expenses |  |  | 175,488 |  |  |  | 84,638,073 |  |  |  | 4,576,719 |  |  |  | 89,390,281 |  |  |  | 427,082 |  |  |  | 937,214 |  |  |  | 1,364,296 |
Loss from Operations |  |  | (185,286 | ) |  |  | (81,503,964 | ) |  |  | (4,576,719 | ) |  |  | (86,265,970 | ) |  |  | (427,082 | ) |  |  | (937,214 | ) |  |  | (1,364,296 | )
Other Income (Expense): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest expense, net |  |  | - |  |  |  | (19,229 | ) |  |  | 29,267 |  |  |  | 10,038 |  |  |  | - |  |  |  | (626,991 | ) |  |  | (626,991 | )
Fair market value adjustment on warrants |  |  | - |  |  |  | - |  |  |  | 16,708 |  |  |  | 16,708 |  |  |  | - |  |  |  | 4,618,889 |  |  |  | 4,618,889 |
Foreign currency loss |  |  | - |  |  |  | - |  |  |  | (8 | ) |  |  | (8 | ) |  |  | - |  |  |  | - |  |  |  | - |
Other Income (Expense), net |  |  | - |  |  |  | (19,229 | ) |  |  | 45,967 |  |  |  | 26,738 |  |  |  | - |  |  |  | 3,991,898 |  |  |  | 3,991,898 |
Income (Loss) Before Provision for Taxes |  |  | (185,286 | ) |  |  | (81,523,193 | ) |  |  | (4,530,752 | ) |  |  | (86,239,232 | ) |  |  | (427,082 | ) |  |  | 3,054,684 |  |  |  | 2,627,602 |
Tax Provision |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |  |  |  | - |
Income (Loss) from Continuing Operations |  |  | (185,286 | ) |  |  | (81,523,193 | ) |  |  | (4,530,752 | ) |  |  | (86,239,232 | ) |  |  | (427,082 | ) |  |  | 3,054,684 |  |  |  | 2,627,602 |
Discontinued Operations: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss from discontinued operations |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (830,769 | ) |  |  | - |  |  |  | (830,769 | )
Income tax benefit |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 132,000 |  |  |  | - |  |  |  | 132,000 |
Loss from Discontinued Operations |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (698,769 | ) |  |  | - |  |  |  | (698,769 | )
Net Income (Loss) |  | $ | (185,286 | ) |  | $ | (81,523,193 | ) |  | $ | (4,530,752 | ) |  | $ | (86,239,232 | ) |  | $ | (1,125,851 | ) |  | $ | 3,054,684 |  |  | $ | 1,928,833 |
The following table presents the total assets by segment (unaudited) at March 31, 2026 and December 31, 2025:
MARCH 31, 2026 |  |  | DECEMBER 31, 2025 |
Medical Device |  |  | Digital Commodities |  |  | Corporate |  |  | Consolidated |  |  | Medical Device |  |  | Digital Commodities |  |  | Corporate |  |  | Consolidated |
$ | 516,543 |  |  | $ | 174,476,910 |  |  | $ | 6,009,157 |  |  | $ | 181,002,610 |  |  | $ | 849,388 |  |  | $ | 257,253,661 |  |  | $ | 10,972,124 |  |  | $ | 269,075,173 |
Note: Net Loss by Segment includes Corporate, although not a reportable segment, only for reconciliation to the condensed consolidated statement of operations.

X
- Definition Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration